Molecular approaches and modern clinical strategies for the management of Helicobacter pylori infection in Japan

Keio Journal of Medicine

Volumn 61, Issue 4, 2012, Pages 109-119

  Suzuki, Hidekazu ^a   Nishizawa, Toshihiro ^b   Tsugawa, Hitoshi ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

CagA; Diagnosis; Eradication; Helicobacter pylori; Indication

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE PLUS METRONIDAZOLE PLUS TETRACYCLINE; CAGA PROTEIN; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REACTIVE OXYGEN METABOLITE; SITAFLOXACIN;

ANTIBIOTIC RESISTANCE; AUTOPHAGY; CHRONIC GASTRITIS; CYTOTOXICITY; DISEASE CONTROL; DRUG SAFETY; DYSPEPSIA; GASTRITIS; GENE MUTATION; HELICOBACTER INFECTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATION; JAPAN; MARGINAL ZONE LYMPHOMA; MINIMUM INHIBITORY CONCENTRATION; OXIDATIVE STRESS; PATHOGENESIS; PEPTIC ULCER; PROTEIN METHYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; STOMACH EPITHELIUM;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; GASTRITIS, ATROPHIC; GENE EXPRESSION REGULATION, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; JAPAN; LYMPHOMA, B-CELL, MARGINAL ZONE; PEPTIC ULCER; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS; VIRULENCE;

EID: 84874888505     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.2012-0001-RE     Document Type: Review

References (67)

1. Suzuki H, Hibi T, Marshall BJ: Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 2007; 42: 1-15.
2. Palmer ED: Investigation of the gastric mucosa spirochetes of the human. Gastroenterology 1954; 27: 218-220.
3. Kasai K, Kobayashi R: The stomach spirochete occurring in mammals. J Parasitol 1919; 6: 1-10.
4. Saito K: Introductory remark of Dr. Rokuzo Kobayashi's achievements. Keio J Med 2002; 51(Suppl 2): 2-3.
5. Suzuki H, Masaoka T, Miyazawa M, Suzuki M, Miura S, Ishii H: Gastric mucosal response to Helicobacter pylori. Keio J Med 2002; 51(Suppl 2): 40-44.
6. Suzuki M, Miura S, Suematsu M, Fukumura D, Kurose I, Suzuki H, Kai A, Kudoh Y, Ohashi M, Tsuchiya M: Helicobacter pylori- associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. Am J Physiol 1992; 263: G719-G725.
7. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA Protein. Science 2002; 295: 683-686.
8. Hatakeyama M: Oncogenic mechanisms of the Helicobacter py- lori CagA protein. Nat Rev Cancer 2004; 4: 688-694.
9. Higashi H, Tsutsumi R, Fujita A, Yamazaki S, Asaka M, Azuma T, Hatakeyama M: Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc Natl Acad Sci USA 2002; 99: 14428-14433.
10. Ishikawa S, Ohta T, Hatakeyama M: Stability of Helicobacter pylori CagA oncoprotein in human gastric epithelial cells. FEBS Lett 2009; 583: 2414-2418.
11. Tsugawa H, Suzuki H, Saya H, Hatakeyama M, Hirayama T, Hirata K, Nagano O, Matsuzaki J, Hibi T: Reactive oxygen species- induced autophagic degradation of Helicobacter pylori CagA is specifcally suppressed in cancer stem-like cells. Cell Host Mi- crob 2012; 12: 764-777.
12. Yamaoka Y: Mechanisms of disease: Helicobacter pylori viru- lence factors. Nat Rev Gastroenterol Hepatol 2010; 7: 629-641.
13. Basso D, Navaglia F, Brigato L, Piva MG, Toma A, Greco E, Di Mario F, Galeotti F, Roveroni G, Corsini A, Plebani M: Analysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profle in benign and malignant gastroduodenal diseases. Gut 1998; 43: 182-186.
14. Suzuki H, Iwasaki E, Hibi T: Helicobacter pylori and gastric cancer. Gastric Cancer 2009; 12: 79-87.
15. Farinati F, Cardin R, Russo VM, Busatto G, Franco M, Rugge M: Helicobacter pylori CagA status, mucosal oxidative damage and gastritis phenotype: a potential pathway to cancer? Helicobacter 2003; 8: 227-234.
16. Suzuki H, Suzuki M, Mori M, Kitahora T, Yokoyama H, Miura S, Hibi T, Ishii H: Augmented levels of gastric mucosal leucocyte activation by infection with cagA gene-positive Helicobacter pylori. J Gastroenterol Hepatol 1998; 13: 294-300.
17. Ding SZ, Minohara Y, Fan XJ, Wang J, Reyes VE, Patel J, Dirden-Kramer B, Boldogh I, Ernst PB, Crowe SE: Helicobacter pylori infection induces oxidative stress and programmed cell death in human gastric epithelial cells. Infect Immun 2007; 75: 4030-4039.
18. Perez-Reyes E, Kalyanaraman B, Mason RP: The reductive me- tabolism of metronidazole and ronidazole by aerobic liver micro- somes. Mol Pharmacol 1980; 17: 239-244.
19. Rao DN, Mason RP: Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, do pamine, and serotonin. A possible mechanism for neurotoxicity caused by nitroheterocyclic drugs. J Biol Chem 1987; 262: 11731-11736.
20. Spiegelhalder C, Gerstenecker B, Kersten A, Schiltz E, Kist M: Purifcation of Helicobacter pylori superoxide dismutase and cloning and sequencing of the gene. Infect Immun 1993; 61: 5315-5325.
21. Ernst FD, Homuth G, Stoof J, Mader U, Waidner B, Kuipers EJ, Kist M, Kusters JG, Bereswill S, van Vliet AH: Iron-responsive regulation of the Helicobacter pylori iron-cofactored superoxide dismutase SodB is mediated by Fur. J Bacteriol 2005; 187: 3687-3692.
22. Tsugawa H, Suzuki H, Satoh K, Hirata K, Matsuzaki J, Saito Y, Suematsu M, Hibi T: Two amino acids mutation of ferric uptake regulator determines Helicobacter pylori resistance to metronida- zole. Antioxid Redox Signal 2011;14: 15-23.
23. Esposito L, Seydel A, Aiello R, Sorrentino G, Cendron L, Zanotti G, Zagari A: The crystal structure of the superoxide dismutase from Helicobacter pylori reveals a structured C-terminal extension. Biochim Biophys Acta 2008; 1784: 1601-1606.
24. Tsugawa H, Suzuki H, Matsuzaki J, Hirata K, Hibi T: FecA1, a bacterial iron transporter, determines the survival of Helicobacter pylori in the stomach. Free Radic Biol Med 2012; 52: 1003-1010.
25. Aldana LP, Kato M, Kondo T, Nakagawa S, Zheng R, Sugiyama T, Asaka M, Kwon DH: In vitro induction of resistance to metronidazole, and analysis of mutations in rdxA and frxA genes from Helicobacter pylori isolates. J Infect Chemother 2005; 11: 59-63.
26. Paulsen IT, Chen J, Nelson KE, Saier MH Jr: Comparative ge- nomics of microbial drug effux systems. J Mol Microbiol Bio- technol 2001; 3: 145-150.
27. van Amsterdam K, Bart A, van der Ende A: A Helicobacter pylori TolC effux pump confers resistance to metronidazole. Antimicrob Agents Chemother 2005; 49: 1477-1482.
28. Hirata K, Suzuki H, Nishizawa T, Tsugawa H, Muraoka H, Saito Y, Matsuzaki J, Hibi T: Contribution of effux pumps to clarithro- mycin resistance in Helicobacter pylori. J Gastroenterol Hepatol 2010; 25(suppl 1): S75-S79.
29. Tsugawa H, Suzuki H, Muraoka H, Ikeda F, Hirata K, Matsuzaki J, Saito Y, Hibi T: Enhanced bacterial efflux system is the first step to the development of metronidazole resistance in Helico- bacter pylori. Biochem Biophys Res Commun 2011; 404: 656-660.
30. Suzuki H, Nishizawa T, Tsugawa H, Mogami S, Hibi T: Roles of oxidative stress in stomach disorders. J Clin Biochem Nutr 2012; 50: 35-39.
31. Suzuki H, Minegishi Y, Nomoto Y, Ota T, Masaoka T, van den Brink GR, Hibi T: Down-regulation of a morphogen (sonic hedge- hog) gradient in the gastric epithelium of Helicobacter pylori-in- fected Mongolian gerbils. J Pathol 2005; 206: 186-197.
32. Nishizawa T, Suzuki H, Masaoka T, Minegishi Y, Iwasahi E, Hibi T: Helicobacter pylori eradication restored sonic hedgehog expression in the stomach. Hepatogastroenterology 2007; 54: 697-700.
33. Nishizawa T, Suzuki H, Nakagawa I, Minegishi Y, Masaoka T, Iwasaki E, Hibi T: Early Helicobacter pylori eradication restores sonic hedgehog expression in the gastric mucosa of Mongolian gerbils.Digestion 2009; 79: 99-108.
34. Nishizawa T, Suzuki H, Nakagawa I, Minegishi Y, Masaoka T, Iwasaki E, Hibi T: Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter py- lori eradication. Digestion 2009; 79: 259-262.
35. Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, Kanai Y, and Hibi, T: Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregula- tion of Mcl-1 in human gastric cancer cells. Oncogene 2009; 28: 2738-2744
36. Belair C, Darfeuille F, Staedel C: Helicobacter pylori and gastric cancer: possible role of microRNAs in this intimate relationship.Clin Microbiol Infect 2009; 15: 806-812.
37. Saito Y, Suzuki H, Hibi T: The role of microRNAs in gastrointestinal cancers. J Gastroenterol 2009; 44(Suppl 19): 18-22.
38. Suzuki H, Saito Y, Hibi T: Helicobacter pylori and gastric mucosa associated lymphoid tissue (MALT) lymphoma: updated review of clinical outcomes and the molecular pathogenesis. Gut Liver 2009; 3: 81-87.
39. Takino H, Okabe M, Li C, Ohshima K, Yoshino T, Nakamura S, Ueda R, Eimoto T, Inagaki H: p16/INK4a gene methylation is a frequent fnding in pulmonary MALT lymphomas at diagnosis. Mod Pathol 2005; 18: 1187-1192.
40. Kaneko Y, Sakurai S, Hironaka M, Sato S, Oguni S, Sakuma Y, Sato K, Sugano K, Saito K: Distinct methylated profles in Helico- bacter pylori dependent and independent gastric MALT lympho- mas. Gut 2003; 52: 641-646.
41. Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A: Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2011; 16(Suppl 1): 65-69.
42. Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y: Effects of a Helicobacter pylori eradication regimen on anti- platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica 2006; 91: 1436-1437.
43. Asahi A, Nishimoto T, Okazaki Y, Suzuki H, Masaoka T, Kawakami Y, Ikeda Y, Kuwana M: Helicobacter pylori eradi- cation shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. J Clin Invest 2008; 118: 2939-2949.
44. Veneri, D., Gottardi, M., Guizzardi, E., Zanuso, C., Krampera, M., and Franchini, M: Idiopathic thrombocytopenic purpura, He- licobacter pylori infection, and HLA class II alleles. Blood 2002; 100:1925-1926; author reply 1926-1927.
45. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. Gastro enterology 2006; 130: 1466-1479.
46. Nishizawa T, Suzuki H, Tsugawa H, Muraoka H, Matsuzaki J, Hirata K, Ikeda F, Takahashi M, Hibi T: Enhancement of amoxicil- lin resistance after unsuccessful Helicobacter pylori eradication. Antimicrob Agents Chemother 2011; 55: 3012-3014.
47. Miwa H, Ghoshal UC, Fock KM, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, Hongo M, Hou X, Kachintorn U, Ke M, Lai KH, Lee KJ, Lu CL, Mahadeva S, Miura S, Park H, Rhee PL, Sugano K, Vilaichone RK, Wong BC, Bak YT: Asian Consensus Report on Functional Dyspepsia. J Gastroenterol Hepatol 2012; 27: 626-641.
48. Suzuki H, Nishizawa T, Hibi T: Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastro- enterol Hepatol 2011; 26(Suppl 3): 42-45.
49. Saito Y, Suzuki H, Tsugawa H, Suzuki S, Matsuzaki J, Hirata K, Hibi T: Dysfunctional gastric emptying with down-regulation of muscle-specific microRNAs in Helicobacter pylori-infected mice. Gastroenterology 2011; 140: 189-198.
50. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, Oakes R, Wilson S, Roalfe A, Bennett C, Forman D: Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Data- base Syst Rev 2006; CD002096.
51. Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T: Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol 2005; 20: 1652-1660.
52. Sugano K: Should we still subcategorize Helicobacter pylori- associated dyspepsia as functional disease? J Neurogastroenterol Motil 2011; 17: 366-371.
53. Suzuki H, Matsuzaki J, Hibi T: What is the difference between Helicobacter pylori-associated dyspepsia and functional dys- pepsia? J Neurogastroenterol Motil 2011; 17: 124-130.
54. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K: Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20.
55. Laheij RJ, Straatman H, Jansen JB, Verbeek AL: Evaluation of commercially available Helicobacter pylori serology kits: a re- view. J Clin Microbiol 1998; 36: 2803-2809.
56. Gisbert JP, Pajares JM: Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004; 9: 347-368.
57. Suzuki H, Masaoka T, Nomura S, Hoshino Y, Kurabayashi K, Minegishi Y, Suzuki M, Ishii H: Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. Keio J Med 2003; 52: 163-173.
58. Nishizawa T, Suzuki H, Suzuki M, Takahashi M, Hibi T: PPIamoxicillinclarithromycin versus PPI-amoxicillin-metronida- zole as frst-line Helicobacter pylori eradication therapy. J Clin Biochem Nutr 2012; 51: 114-116.
59. Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, Megraud F: Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin- based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913.
60. Suzuki H, Matsuzaki J, Hibi T: Metronidazole-based quadruple versus standard triple therapy: which is better as first-line therapy for Helicobacter pylori eradication? Expert Rev Clin Pharmacol 2011; 4: 579-582.
61. Hiyama T, Tanaka S, Masuda H, Shima H, Kose K, Tuncel H, Ito M, Kitadai Y, Sumii M, Uemura N, Yoshihara M, Shimamoto F, Haruma K, Chayama K: Prevalence of Helicobacter pylori resis- tance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan. J Gastro- enterol Hepatol 2003; 18: 1202-1207.
62. Matsuhisa T, Kawai T, Masaoka T, Suzuki H, Ito M, Kawamura Y, Tokunaga K, Suzuki M, Mine T, Takahashi S, Sakaki N: Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multi- center study in the Tokyo Metropolitan Area. Helicobacter 2006; 11: 152-158.
63. Nishizawa T, Suzuki H, Masaoka T, Iwasaki E, Hibi T: A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori. Digestion 2007; 76: 215-220.
64. Nishizawa T, Suzuki H, Nakagawa I, Iwasaki E, Masaoka T, Hibi T: Gatifoxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication. J Gastroenterol Hepatol 2008; 23(Suppl 2): S167-S170.
65. Suzuki H, Nishizawa T, Muraoka H, Hibi T: Sitafoxacin and garenoxacin may overcome the antibiotic resistance of Helico- bacter pylori with gyrA mutation. Antimicrob Agents Chemother 2009; 53: 1720-1721.
66. Nishizawa T, Suzuki H, Hibi T: Quinolone-based third-line therapy for Helicobacter pylori eradication. J Clin Biochem Nutr 2009; 44: 119-124.
67. Matsuzaki J, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, Saito Y, Okada S, Fukuhara S, Hibi T: Effcacy of sitafoxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother 2012; 56: 1643-1645.